NCT04294875View on ClinicalTrials.gov

Phase I, FIH, MTD for MPT0B640, Multi-centre, Open-label, Subject With Locally Advanced or Metastatic Solid Malignancies

EARLY_PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 31, 2025

Primary Completion Date

November 30, 2027

Study Completion Date

November 30, 2027

Conditions
Advanced Solid TumorMetastatic Solid Tumor
Interventions
DRUG

MPT0B640

PO, every 3 days. dose escalation per MTD

Sponsors

Lead Sponsor

J Ints Bio
All Listed Sponsors
lead

J Ints Bio

INDUSTRY